Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Remon, Jordi
- dc.contributor.author García-Campelo, Rosario
- dc.contributor.author Álava, Enrique de
- dc.contributor.author Vera, R.
- dc.contributor.author Rodríguez Peraltó, José Luís
- dc.contributor.author Rodríguez-Lescure, Álvaro
- dc.contributor.author Bellosillo Paricio, Beatriz
- dc.contributor.author Garrido, P.
- dc.contributor.author Rojo, Federico
- dc.contributor.author Álvarez-Alegret, R.
- dc.date.accessioned 2020-05-07T07:05:27Z
- dc.date.issued 2020
- dc.description.abstract The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is growing considerably. The diagnosis of these genomic alterations can lead to tailored treatment at the onset of disease or on progression and to obtaining additional predictive information on immunotherapy efficacy. However, in up to 25% of cases, the initial tissue biopsy is inadequate for precision oncology and, in many cases, tumour genomic profiling at progression is not possible due to technical limitations of obtaining new tumour tissue specimens. Efficient diagnostic alternatives are therefore required for molecular stratification, which includes liquid biopsy. This technique enables the evaluation of the tumour genomic profile dynamically and captures intra-patient genomic heterogeneity as well. To date, there are several diagnostic techniques available for use in liquid biopsy, each one of them with different precision and performance levels. The objective of this consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology is to evaluate the viability and effectiveness of the different methodological approaches in liquid biopsy in cancer patients and the potential application of this method to current clinical practice. The experts contributing to this consensus statement agree that, according to current evidence, liquid biopsy is an acceptable alternative to tumour tissue biopsy for the study of biomarkers in various clinical settings. It is therefore important to standardise pre-analytical and analytical procedures, to ensure reproducibility and generate structured and accessible clinical reports. It is essential to appoint multidisciplinary tumour molecular boards to oversee these processes and to enable the most suitable therapeutic decisions for each patient according to the genomic profile.
- dc.format.mimetype application/pdf
- dc.identifier.citation Remon J, García-Campelo R, de Álava E, Vera R, Rodríguez-Peralto JL, Rodríguez-Lescure Á, et al. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020 Jun;22(6):823-34. DOI: 10.1007/s12094-019-02211-x
- dc.identifier.doi http://dx.doi.org/10.1007/s12094-019-02211-x
- dc.identifier.issn 1699-048X
- dc.identifier.uri http://hdl.handle.net/10230/44442
- dc.language.iso eng
- dc.publisher Springer
- dc.rights © Springer The final publication is available at Springer via http://dx.doi.org/10.1007/s12094-019-02211-x
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Genomic profiling
- dc.subject.keyword Liquid biopsy
- dc.subject.keyword Oncology
- dc.subject.keyword Precision medicine
- dc.subject.keyword ctDNA
- dc.title Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion